quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:08·86d
SECFiling
Pasithea Therapeutics Corp. logo

SEC Form EFFECT filed by Pasithea Therapeutics Corp.

KTTA· Pasithea Therapeutics Corp.
Health Care
Original source

Companies

  • KTTA
    Pasithea Therapeutics Corp.
    Health Care

Recent analyst ratings

  • Dec 14UpdateEF Hutton$3.25

Related

  • PR4d
    Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
  • INSIDER6d
    SEC Form 3 filed by new insider Coastlands Capital Lp
  • SEC15d
    SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.
  • PR23d
    Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
  • SEC24d
    SEC Form 10-K filed by Pasithea Therapeutics Corp.
  • SEC62d
    Pasithea Therapeutics Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • SEC65d
    Amendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.
  • SEC65d
    SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022